Protein S100B Versus Neutrophils/Lymphocytes Ratio in Early Prediction of Brain Injury
NCT ID: NCT07093723
Last Updated: 2025-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2023-09-01
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
S100B in Intensive Care Patients With and Without Traumatic Brain Injury
NCT04501315
S-100B as Pre-Head CT Scan Screening Test After Mild Traumatic Brain Injury
NCT00717301
S100 Protein in Minor/Mild Traumatic Brain Injury
NCT00822445
Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time in Emergency Settings
NCT07138768
Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement
NCT07313098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Amplitude-integrated EEG (aEEG) is another early predictor and prognostic technique for Neonatal Brain Injury. Electrophysiological brain activity, as measured by aEEG, is a well-established method for giving information on the functional and metabolic status of the brain and the incidence of epileptic seizure episodes.
S100B belongs to the S100 family. Because it is soluble in a 100% saturated solution of ammonium sulfate, it was designated "S100." S100 protein is a calcium-binding cytosolic protein with a molecular weight of 21 kDa comprised of 2 monomers, which are found in a variety of cells and are primarily concentrated in the glial cells of the CNS. Due to its molecular weight, peripheral blood will detect only S100B.
The neutrophil-to-lymphocyte ratio (NLR) reflects changes in neutrophil and lymphocyte levels, which is an indication of inflammation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
Preterm neonates, their gestational age between 28- 36 gestational weeks
S100B Protein
Serum level of S100B Protein was measured on the first and third days of seizure activity by ELISA.
Neutrophils to Lymphocytes ratio
Neutrophils to Lymphocytes ratio was measured on the first and third day of seizure activity obtained by complete blood count.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
S100B Protein
Serum level of S100B Protein was measured on the first and third days of seizure activity by ELISA.
Neutrophils to Lymphocytes ratio
Neutrophils to Lymphocytes ratio was measured on the first and third day of seizure activity obtained by complete blood count.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prematurity.
Exclusion Criteria
* Multiple congenital anomalies.
* Chromosomal abnormalities.
* Preterm less than 28 weeks.
* Infant of diabetic mother.
28 Weeks
36 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asmaa Mahmoud Abdel Hamid Elmesiry
Lecturer of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El-Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36264PR392/10/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.